Haisma HJ - Search Results

1

Novel anthracycline-spacer-beta-glucuronide,-beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy.

Leenders RG, Damen EW, Bijsterveld EJ, Scheeren HW, Houba PH, van der Meulen-Muileman IH, Boven E, Haisma HJ. Leenders RG, et al. Among authors: haisma hj. Bioorg Med Chem. 1999 Aug;7(8):1597-610. doi: 10.1016/s0968-0896(99)00095-4. Bioorg Med Chem. 1999. PMID: 10482452

2

Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT.

de Bont DB, Leenders RG, Haisma HJ, van der Meulen-Muileman I, Scheeren HW. de Bont DB, et al. Among authors: haisma hj. Bioorg Med Chem. 1997 Feb;5(2):405-14. doi: 10.1016/s0968-0896(96)00249-0. Bioorg Med Chem. 1997. PMID: 9061205

3

A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.

de Graaf M, Nevalainen TJ, Scheeren HW, Pinedo HM, Haisma HJ, Boven E. de Graaf M, et al. Among authors: haisma hj. Biochem Pharmacol. 2004 Dec 1;68(11):2273-81. doi: 10.1016/j.bcp.2004.08.004. Biochem Pharmacol. 2004. PMID: 15498517

4

Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.

Haisma HJ, van Muijen M, Pinedo HM, Boven E. Haisma HJ, et al. Cell Biophys. 1994;24-25:185-92. doi: 10.1007/BF02789229. Cell Biophys. 1994. PMID: 7736523

5

Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.

Houba PH, Leenders RG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: haisma hj. Biochem Pharmacol. 1996 Aug 9;52(3):455-63. doi: 10.1016/0006-2952(96)00248-1. Biochem Pharmacol. 1996. PMID: 8687500

6

The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

Houba PH, Boven E, Erkelens CA, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: haisma hj. Br J Cancer. 1998 Dec;78(12):1600-6. doi: 10.1038/bjc.1998.729. Br J Cancer. 1998. PMID: 9862570 Free PMC article.

7

A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.

Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: haisma hj. Br J Cancer. 2001 Feb;84(4):550-7. doi: 10.1054/bjoc.2000.1640. Br J Cancer. 2001. PMID: 11207053 Free PMC article.

8

Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.

Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: haisma hj. Int J Cancer. 2001 Feb 15;91(4):550-4. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1075>3.0.co;2-l. Int J Cancer. 2001. PMID: 11251980

9

Beta-glucuronidase-mediated drug release.

de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. de Graaf M, et al. Among authors: haisma hj. Curr Pharm Des. 2002;8(15):1391-403. doi: 10.2174/1381612023394485. Curr Pharm Des. 2002. PMID: 12052215 Review.

10

Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin.

de Graaf M, Pinedo HM, Quadir R, Haisma HJ, Boven E. de Graaf M, et al. Among authors: haisma hj. Biochem Pharmacol. 2003 Jun 1;65(11):1875-81. doi: 10.1016/s0006-2952(03)00183-7. Biochem Pharmacol. 2003. PMID: 12781339

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters